Compare MGM Resorts International (MGM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Sana Biotechnology Inc — how do they compare? MGM Resorts International trades at $29.3 (market cap $7.55B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: MGM Resorts International is far larger — about 9× Sana Biotechnology Inc's market cap, and MGM Resorts International pays a 0.03% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MGM Resorts International for 91 Days and Sana Biotechnology Inc for 23 Days on average.
| MGM | SANA | |
|---|---|---|
Market Cap | $7.55B | $836.71M |
Volume | 5,342,346 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $5.92 |
52-Week Low | $30.00 | $2.68 |
Typical Hold Time | 91 Days | 23 Days |
Enterprise Value | $34.85B | $749.96M |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) stock is trading at $29.27, down 2.43% on the day and reflecting significant pressure following the collapse of Barry Diller's $48.30 per share acquisition proposal in late September 2026. The technical picture is bearish, while fundamentals show mixed signals with revenue growth to $17.54B in 2025 but declining net income margins. Analyst sentiment remains predominantly positive with a consensus price target of $48.75, suggesting substantial upside potential from current levels.
The investment case hinges on MGM's ability to execute its strategic initiatives and potentially pursue acquisitions like People Inc. to unlock value. Near-term risks include integration challenges, market volatility, and execution missteps. The current valuation at a P/E of 18.19 and P/S of 0.45 appears reasonable if management can stabilize profitability and navigate the post-deal uncertainty.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
